Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2018 5
2019 3
2020 2
2021 8
2022 5
2023 6
2024 3
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Long-term use of lokivetmab in dogs with atopic dermatitis.
Kasper B, Zablotski Y, Mueller RS. Kasper B, et al. Vet Dermatol. 2024 Dec;35(6):683-693. doi: 10.1111/vde.13286. Epub 2024 Aug 14. Vet Dermatol. 2024. PMID: 39143659
OBJECTIVES: To investigate the efficacy and safety of lokivetmab during long-term treatment defined as at least three consecutive lokivetmab injections in atopic dogs under field conditions. ...RESULTS: Lokivetmab reduced the PVAS score with long-term use (p …
OBJECTIVES: To investigate the efficacy and safety of lokivetmab during long-term treatment defined as at least three consecutive …
Long term use of lokivetmab (Cytopoint ) in atopic dogs.
Gober M, Amodie D, Mellencamp M, Hillier A. Gober M, et al. BMC Vet Res. 2025 Mar 26;21(1):203. doi: 10.1186/s12917-025-04645-8. BMC Vet Res. 2025. PMID: 40133889 Free PMC article.
The objective of this study was to follow a cohort of dogs receiving lokivetmab to treat their canine atopic dermatitis (CAD) over 12 months. The initial phase of this interventional cohort study evaluated a dog's pruritus following monthly injections (up to 3 injections) …
The objective of this study was to follow a cohort of dogs receiving lokivetmab to treat their canine atopic dermatitis (CAD) over 12 …
Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma.
Inai K, Kitagawa K, Murakami M, Iwasaki T. Inai K, et al. J Vet Med Sci. 2022 Jan 7;84(1):36-39. doi: 10.1292/jvms.21-0346. Epub 2021 Dec 6. J Vet Med Sci. 2022. PMID: 34866072 Free PMC article.
To address the worsening condition of pruritus, lokivetmab was started in combination with prednisolone. Once on lokivetmab, the pruritus steadily improved and was effective in resolving and maintaining remission. ...
To address the worsening condition of pruritus, lokivetmab was started in combination with prednisolone. Once on lokivetmab, t …
Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs.
Krautmann M, Walters RR, King VL, Esch K, Mahabir SP, Gonzales A, Dominowski PJ, Sly L, Mwangi D, Foss DL, Rai S, Messamore JE, Gagnon G, Schoell A, Dunham SA, Martinon OM. Krautmann M, et al. Vet Immunol Immunopathol. 2023 Apr;258:110574. doi: 10.1016/j.vetimm.2023.110574. Epub 2023 Feb 21. Vet Immunol Immunopathol. 2023. PMID: 36842258 Free article.
Lokivetmab (Cytopoint , Zoetis) is a canine monoclonal antibody that specifically binds and neutralizes interleukin (IL)-31. Lokivetmab is approved for use in dogs for the treatment of atopic dermatitis (AD) and allergic dermatitis. ...
Lokivetmab (Cytopoint , Zoetis) is a canine monoclonal antibody that specifically binds and neutralizes interleukin (IL)-31. Lokiv …
Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs.
Bruet V, Mosca M, Briand A, Bourdeau P, Pin D, Cochet-Faivre N, Cadiergues MC. Bruet V, et al. Vet Sci. 2022 Mar 22;9(4):149. doi: 10.3390/vetsci9040149. Vet Sci. 2022. PMID: 35448647 Free PMC article. Review.
The molecules reviewed here are systemic and topical glucocorticoids, antihistamines, ciclosporin, oclacitinib and lokivetmab. A level of evidence (1, 2 or 3) has been established according to a detailed algorithm for each individual study in the literature published betwe …
The molecules reviewed here are systemic and topical glucocorticoids, antihistamines, ciclosporin, oclacitinib and lokivetmab. A leve …
Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis.
Meichner K, Kiupel M, Kasantikul T, Rakich P, Banovic F. Meichner K, et al. Vet Dermatol. 2019 Feb;30(1):73-e22. doi: 10.1111/vde.12702. Epub 2018 Nov 26. Vet Dermatol. 2019. PMID: 30479052
Treatment was initiated with anti-canine-interleukin (IL)-31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's pruritus resolved within seven days and was maintained in remission over 15 months with once monthly lokivetmab injections; the skin …
Treatment was initiated with anti-canine-interleukin (IL)-31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's …
Weekly topical therapy based on plant extracts combined with lokivetmab in canine atopic dermatitis.
Bensignor E, Videmont E. Bensignor E, et al. Vet Dermatol. 2022 Feb;33(1):68-e22. doi: 10.1111/vde.13004. Epub 2021 Aug 19. Vet Dermatol. 2022. PMID: 34414621
BACKGROUND: Lokivetmab is an effective treatment for atopic dermatitis (AD) in dogs. The aim of this prospective study was to determine if topical products containing plant extracts could enhance the clinical efficacy of lokivetmab. ...A longer-lasting remission was …
BACKGROUND: Lokivetmab is an effective treatment for atopic dermatitis (AD) in dogs. The aim of this prospective study was to determi …
Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus.
Fleck TJ, Norris LR, Mahabir S, Walters RR, Martinon O, Dunham SA, Gonzales AJ. Fleck TJ, et al. Vet Dermatol. 2021 Dec;32(6):681-e182. doi: 10.1111/vde.12943. Epub 2021 Apr 8. Vet Dermatol. 2021. PMID: 33830571 Free PMC article.
METHODS AND MATERIALS: Randomized, blinded, placebo-controlled studies were designed to evaluate the antipruritic properties of lokivetmab. Laboratory beagle dogs were given either placebo, 0.125, 0.5 or 2.0 mg/kg lokivetmab, subcutaneously. ...RESULTS: When animals …
METHODS AND MATERIALS: Randomized, blinded, placebo-controlled studies were designed to evaluate the antipruritic properties of lokivetma …
Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab.
Calesso JR, Marques VS, de Carvalho OV, Costa-Val AP. Calesso JR, et al. Pol J Vet Sci. 2023 Jun;26(2):231-238. doi: 10.24425/pjvs.2023.145027. Pol J Vet Sci. 2023. PMID: 37389418
To the author's knowledge, there are no studies that measured serum IL-31 in dogs treated with lokivetmab injections, a selective inhibitor of this key cytokine in pruritus. The aim of the study was to evaluate serum IL-31 levels in dogs treated with lokivetmab and …
To the author's knowledge, there are no studies that measured serum IL-31 in dogs treated with lokivetmab injections, a selective inh …
Evaluation of the clinical efficiency of lokivetmab in client privately owned atopic dogs - multicenter study.
Szczepanik MP, Popiel J, Cekiera A, Pomorska-Handwerker D, Karaś-Tęcza J, Ściskalska M, Oczkowska K, Taube M, Olender V, Parys P. Szczepanik MP, et al. Pol J Vet Sci. 2020 Jun;23(2):191-195. doi: 10.24425/pjvs.2020.132765. Pol J Vet Sci. 2020. PMID: 32627992
AD can be treated using allergenspecific immunotherapy as well as symptomatic antipruritic treatment including the use of lokivetmab - caninized anti-interleukine-31 antibody.The aim of the study was to evaluate the effectiveness of lokivetmab over 12 weeks of treat …
AD can be treated using allergenspecific immunotherapy as well as symptomatic antipruritic treatment including the use of lokivetmab …
36 results